Breaking Out, Episode 1: Winlevi (clascoterone) — labelled in more than one country, still a funding fight

For a lot of people 12 to 25, acne is not a “wait it out” problem. It is school, work, dating, and a bathroom shelf of retinoids, benzoyl peroxide, and antibiotics that either sting or stop working. The newish option people keep hearing about is Winlevi (clascoterone 1% cream): the first topical that tries to block androgen signals in the skin, so it can be used by males and females, unlike spironolactone (a pill used off-label mostly in women).

The science paper is from 2020. The 2026 story is access. The cream is labelled in the US, Canada, the UK, and the EU. In Canada, the national reimbursement committee still said no. If someone told you “it’s approved, so you’re covered,” they skipped a step.

Where this is taking place

Pivotal trials ran as two identical Phase 3 programmes (NCT02608450 / NCT02608476) in people with facial acne. They did not enrol nodulocystic acne or people with two or more facial nodules. Concurrent other acne drugs were not allowed. Long-term follow-up (NCT02682264) let people keep using the cream on the face and, if they wanted, the trunk.

Commercial cream: prescription product. Not a trial slot. No open Canadian clascoterone acne trial; the pivotals had no Canadian sites. SAP is the wrong door in Canada — the drug is marketed. A CDA-AMC do-not-reimburse is not a prescribing ban — GP or derm can prescribe.

Approval matrix (acne vulgaris)

Do not collapse labels. A Canadian or US 12+ “affected area” prescription is not the same as an EU adolescent face-only licence. Use the label of the country that will prescribe.

Access by country

• Canada: GP or dermatologist can prescribe the labelled use (12+). CDA-AMC do not reimburse is not a prescribing ban. pCPA 22933: negotiations not pursued (concluded 4 Jul 2025). BC PharmaCare non-benefit 19 Nov 2025. Ontario Formulary: no row (do not write “EAP will not fund”). RAMQ checker: not among covered; INESSS avis 12 Aug 2026 is not inscrire/refus. Alberta/Atlantic/NIHB unknown. Private insurance / cash. Clinic enrols SUN PHARMA Patient Benefit Program (winlevi.ca, DIN 02538881; no dollar amounts). SAP is the wrong door. Under 12: not labelled. No open Canadian trial; pivotals had no Canadian sites.
• United States: FDA-labelled 12+. Dermatology or a clinician who already manages acne; US prior authorization still applies. US copay (PhilRx $0–$90 and similar offers) is US-only — do not quote it as a Canadian path. Sun US 1-800-818-4555 is adverse-event reporting, not access.
• United Kingdom: MHRA-labelled 12+ (Jan 2025). NHS/specialist commissioning not confirmed here. Ask the prescriber.
• EU/EEA: Commission licence 17 Oct 2025. Adults: acne. Ages 12–<18: face only. Started and supervised by a doctor experienced in acne. Must not be used in pregnancy; EU patients get a card about contraception during treatment and for at least 10 days after stopping. National reimbursement will lag — unknown here unless a country file is opened.
• Australia: ARTG 403948, 12 Mar 2024, Sun Pharma ANZ, 12+. Specialist prescription. PBS unknown / not confirmed on this page (licence ≠ subsidy). Cosmo 19 Mar 2024 is company news, not ARTG.
• If your regulator has not labelled it: do not import on your own. Ask about a labelled market only as a medical/legal plan with a local clinician.

---

What it actually is

Clascoterone is an androgen receptor inhibitor in a cream. Androgens tell oil glands to make sebum. Winlevi is built to compete with DHT at those receptors locally. The precise anti-acne mechanism is still listed as unknown on the US label.

It is not:

• isotretinoin (Accutane)
• spironolactone
• an antibiotic
• a retinoid
• a treatment established under age 12
• a public benefit in Canada just because Health Canada said yes

Dose on the US and Canadian labels: cleanse, dry, thin layer twice a day, morning and evening, about 1 gram per application on the US label. Avoid eyes, mouth, mucous membranes. Do not put it on cuts, eczema, or sunburn.

Storage (US label): fridge before the pharmacy dispenses (2–8 °C). At home, room temperature 20–25 °C. Do not freeze. Discard unused cream 180 days after dispensing or 1 month after first opening, whichever is sooner. Ask the pharmacist how they stored it.

---

What the trials showed (plain numbers)

The Canadian and US labels rest on two identical Phase 3 trials.

IDs. NCT02608450 (CB-03-01/25) and NCT02608476 (CB-03-01/26). Sponsor: Cassiopea SpA. Published: Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne. JAMA Dermatol. 2020;156(6):621-630. doi:10.1001/jamadermatol.2020.0465.

Research team (paper, not a clinic directory).

• First author: Adelaide A. Hebert, UTHealth McGovern Medical School, Houston.
• Co-authors include Diane Thiboutot and Linda Stein Gold (Henry Ford).
• Industry: Cassiopea (now in the Cosmo group); commercial rights with Sun Pharma in several markets.
• Names as they appear on primary sources.

Who got in. Age 9+ in the protocol; labels use 12+. Moderate or severe facial acne (IGA 3 or 4), 30–75 inflammatory lesions, 30–100 non-inflammatory lesions. Kept out: two or more facial nodules, nodulocystic acne, other acne drugs during the 12 weeks.

Who was in the 12+ analysis (DailyMed / HC SBD). 1,421 people 12+; 45% were 12–17; 55% 18+; about 62% female; about 91% Caucasian. Mean inflammatory lesions ~42; non-inflammatory ~61.

Week 12 (DailyMed, ages 12+):

Health Canada’s pooled 12+ IGA success: 19.8% vs 7.8% vehicle. That is a real difference. It is also modest. Most people were not “clear” at week 12. EMA’s overview uses the same shape of numbers (about 19.5% vs 7.7%).

Limitations the regulators already flagged. Facial acne trial, not a back-acne registrational study. Few people with darker Fitzpatrick types; effect estimates looked less favourable in some racialized subgroups (HC SBD). Not for nodules/cysts. Not a head-to-head vs tretinoin, BPO, or isotretinoin.

Long-term extension (NCT02682264; Eichenfield et al., J Drugs Dermatol. 2023): open-label, up to 12 months on the face, trunk optional. Useful for safety/continuation, not a new pivotal.

---

Safety a household should actually watch

Local: redness, dryness/scaling, itch, sting/burn. On the US table these were common on vehicle too. If it peels or burns, the label says stop or use less often — ask the prescriber, do not tough it out on broken skin.

HPA axis (adrenal) suppression: seen in a small pharmacokinetic study (1/20 adults, 2/22 adolescents at day 14 under heavy use). All back to normal four weeks after stopping. Pediatric patients may be more susceptible. Large areas, long use, occlusive dressings increase absorption. This is why under-12 is not labelled, and why the EU limited teens to the face.

Potassium: some lab shifts to high potassium. Usually no symptoms in the trials.

Pregnancy:

• EU: must not be used. Patient card; contraception during treatment and ≥10 days after stopping.
• US / Canada: human data insufficient; animal studies showed malformations at high subcutaneous doses. Tell the clinic if you are pregnant or trying.

EU extra: educational materials for prescribers; additional monitoring.

This is still a cream, not Accutane. It is not “no systemic risk.”

---

Access: what you can actually do

1. This is a labelled, marketed cream. SAP is the wrong door in Canada.

Health Canada’s Special Access Programme is for drugs not marketed in Canada. Winlevi has been sold here since 8 September 2023. The usual path is: prescription of a labelled product, then a fight over payment.

2. Who to see

A family doctor, nurse practitioner, or dermatologist who already treats acne can prescribe a labelled topical. Do not reimburse is not a prescribing ban. You do not need an isotretinoin clinic. If they have never heard of clascoterone, ask them to look up the Canadian Product Monograph or the FDA DailyMed page — not a TikTok.

Bring: current cream/pill list, how long you have used each, whether you have cysts/nodules, pregnancy/contraception status, and whether the acne is face, chest, back, or all three.

3. Script for the visit

Health Canada authorized Winlevi (clascoterone 1%) on 15 June 2023 for acne in people 12 and older. The FDA labelled it in 2020. CDA-AMC told public plans not to reimburse it. I am 12 or older, I do not have nodulocystic acne, and I want to know if I fit the labelled population. If I do, can you prescribe it, and what is the realistic funding path — private insurance, the SUN PHARMA Patient Benefit Program on winlevi.ca, or cash? I understand CDA-AMC said public plans should not pay, and an NOC is not coverage. If I am 12–17 and in the EU, I also understand the licence is face-only and pregnancy is barred.

Ask:

• Do I have nodules/cysts that put me outside what the trials studied?
• Is this instead of, or on top of, a retinoid/BPO? (US label: limit other irritating topicals.)
• Face vs trunk — which label applies in this country?
• How do we store it, and when do we throw the tube out?
• Pregnancy / contraception, especially if you might be in the EU labelling?

4. Public coverage: start from “no” in Canada

• CDA-AMC SR0863: Do not reimburse for acne vulgaris 12+. Final to plans 6 Feb 2025. Procedural review upheld 19 Jun 2025. That is not a prescribing ban.
• pCPA file 22933: negotiations not pursued, concluded 4 Jul 2025.
• BC PharmaCare: non-benefit effective 19 Nov 2025, DIN 02538881. PAD ~$275/30 g (McKesson, 22 Jun 2026) is BC wholesale, not an ODB list and not the CDA submitted price.
• Ontario Formulary: no row. Do not write “EAP will not fund.”
• Quebec: RAMQ public checker: not among covered. INESSS avis to the minister 12 Aug 2026 — do not treat as inscrire or refus. CDA is not Quebec’s decision.
• Alberta / Atlantic / NIHB: unknown / not confirmed on this page.
• Submitted-to-CDA price (not an ODB list): $242.42 per 30 g tube. Sponsor’s annual figure up to $5,899. CDA reanalysis average $3,539/year. Do not call any of these an Ontario Drug Benefit price.
• US: commercial prior auth. US copay (PhilRx $0–$90 etc.) is US-only.
• EU/UK public listing: not confirmed. Australia PBS unknown / not confirmed on this page. Licence ≠ reimbursement.

NOC ≠ public funding. Repeat it.

5. Private insurance and cash

Ask the clinic to submit a prior authorization using the acne vulgaris / clascoterone / 12+ indication, not “hormonal acne” or spironolactone language. Insurers default to old criteria.

Submitted-to-CDA (not ODB list): $242.42 per 30 g; sponsor annual up to $5,899; CDA reanalysis avg $3,539/year.

Canadian copay: SUN PHARMA Patient Benefit Program at winlevi.ca, gated to DIN 02538881. The clinic enrols. No dollar amounts on that page — do not invent a copay floor. US PhilRx-style $0–$90 offers are US-only. Sun 1-800-818-4555 is AE reporting, not access.

6. Clinical trials

The registrational studies are completed. NCT02608450, NCT02608476, NCT02682264 are not a 2026 enrolment path. No Canadian sites on those pivotals. No open Canadian clascoterone acne trial as of 2 Sep 2026. If a new trial opens, it will have its own NCT. Search ClinicalTrials.gov with the prescriber; do not travel on a rumour.

7. If the answer is “not a candidate”

Under 12, nodulocystic/severe nodular disease, or pregnancy (especially under the EU label) need a different plan — usually a retinoid/BPO combination, hormonal therapy where it fits, or isotretinoin (Episode 3, not this one). Winlevi is not a substitute for Accutane.

---

Bottom line

Winlevi is a real, labelled, twice-daily cream for people 12 and older with acne vulgaris. It is the first topical androgen blocker, so it is not “the pill” and it is not only for girls. In two Phase 3 trials, about one in five people on drug hit “clear or almost clear” at 12 weeks versus under one in ten on vehicle. That is why regulators said yes. It is also why this is not a miracle.

The 2026 fight is money and fine print. Canada authorized it in June 2023 and CDA-AMC still said public plans should not pay. The EU authorized it on 17 October 2025 but limited teens to the face and barred pregnancy. The UK licensed it in January 2025. Use the label of the country that will prescribe. Ask a clinician who treats acne to write the prescription if you fit that label, and start the insurance paperwork the same week — not after someone tells you “it’s approved, so you’re fine.”

---

Primary sources

1. Health Canada. Summary Basis of Decision for Winlevi (clascoterone). NOC 2023-06-15; DIN 02538881; first sale 2023-09-08. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1693490140440

2. Health Canada Drug Product Database. WINLEVI, DIN 02538881, monograph date 2023-06-15. https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=0164781001

3. US FDA. NDA 213433 approval letter, 26 Aug 2020. DailyMed WINLEVI (clascoterone) cream. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1673a84b-7f5c-47ab-a99c-1e3db21a6a09

4. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020;156(6):621-630. doi:10.1001/jamadermatol.2020.0465

5. ClinicalTrials.gov. NCT02608450. https://clinicaltrials.gov/study/NCT02608450

6. ClinicalTrials.gov. NCT02608476. https://clinicaltrials.gov/study/NCT02608476

7. ClinicalTrials.gov. NCT02682264 (long-term extension). https://clinicaltrials.gov/study/NCT02682264

8. CDA-AMC. clascoterone (Winlevi), SR0863-000. Do not reimburse. Final 6 Feb 2025; procedural review concluded 19 Jun 2025. https://www.cda-amc.ca/clascoterone-0

9. European Medicines Agency. Winlevi EPAR. EC marketing authorisation 17 Oct 2025. EMEA/H/C/006138. https://www.ema.europa.eu/en/medicines/human/EPAR/winlevi

10. EMA. Questions and answers: approval of the marketing authorisation for Winlevi (clascoterone). 26 Aug 2025. https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-approval-marketing-authorisation-winlevi-clascoterone_en.pdf

11. MHRA. Public Assessment Report, Winlevi 10 mg/g cream, PL 25258/0425. MA 30 Jan 2025. https://winlevi.co.uk/files/download/Public-Assessment-Report-PL25258-0425.pdf

12. Eichenfield LF, Hebert AA, Stein Gold L, et al. Long-term safety and efficacy of twice-daily topical clascoterone cream 1% in patients ≥12 years of age with acne vulgaris. J Drugs Dermatol. 2023;22(8):810-816.

13. Therapeutic Goods Administration. ARTG ID 403948, Winlevi (clascoterone), Sun Pharma ANZ. Start 12 Mar 2024. 12+. Cosmo 19 Mar 2024 is company news, not ARTG. PBS unknown / not confirmed on this page.

14. CDA-AMC SR0863 combined review: submitted price $242.42 / 30 g; sponsor annual up to $5,899; CDA reanalysis avg $3,539/year. Submitted-to-CDA, not an ODB list.

15. SUN PHARMA Patient Benefit Program (Canada). winlevi.ca. DIN 02538881 gate. Clinic enrols. No dollar amounts on that page.

16. pCPA. File 22933, clascoterone / Winlevi. Negotiations not pursued; concluded 4 Jul 2025.

17. BC PharmaCare non-benefit, DIN 02538881, effective 19 Nov 2025. PAD ~$275/30 g McKesson 22 Jun 2026 is BC wholesale, not ODB.

18. INESSS avis to the Quebec minister, 12 Aug 2026 (not inscrire/refus). RAMQ public checker: not among covered.

Cosmo 19 Mar 2024 (TGA) and 21 Oct 2025 (EC) newswires are company news. ARTG date is 12 Mar 2024. EC date used is the EMA EPAR (17 Oct 2025).